Payment overview · 2025
General Payments
$1,857.90
119 reported records · 27 companies
Healthcare provider profile · identity verified
Jason Booth, MD
Allopathic & Osteopathic Physicians|Family Medicine · CEDAR RAPIDS, IA · NPI 1861460495
Verified facts
What the public records show
CMS Open Payments records show Jason Booth, MD received $1,857.90 in general payments during 2025 across 119 reported records.
PFIZER INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Synthroid, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $306.87 | 16.5% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $246.22 | 13.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.06 | 12.9% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $222.75 | 12.0% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.95 | 5.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.11 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.74 | 3.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.44 | 3.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.68 | 3.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.70 | 2.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.56 | 2.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.12 | 2.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.34 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.90 | 1.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.66 | 1.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.43 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.57 | 1.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.37 | 1.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.32 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.04 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.03 | 1.1% | 1 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $19.81 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.81 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.04 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.78 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.36 | 0.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.24 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,857.90 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $172.70 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $171.29 | 15 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $170.88 | 20 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $151.04 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $143.27 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.02 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $123.00 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.31 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.18 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $94.69 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $94.69 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $79.90 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $77.59 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.04 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.68 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $54.71 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.87 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.70 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.56 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.95 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.14 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.27 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $12.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 54 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1045 | 261 |
| Losartan Potassium | Losartan Potassium | 606 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 114 |
| Omeprazole | Omeprazole | 475 | 129 |
| Gabapentin | Gabapentin | 385 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 105 |
| Lisinopril | Lisinopril | 351 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 82 |
| Simvastatin | Simvastatin | 321 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 244 | 64 |
| Metformin Hcl | Metformin Hcl | 223 | 52 |
| Alprazolam | Alprazolam | 216 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 54 |
| Trazodone Hcl | Trazodone Hcl | 198 | 51 |
| Montelukast Sodium | Montelukast Sodium | 193 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 32 |
| Sertraline Hcl | Sertraline Hcl | 182 | 40 |
| Meloxicam | Meloxicam | 181 | 42 |
| Alendronate Sodium | Alendronate Sodium | 171 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 54 |
| Tramadol Hcl | Tramadol Hcl | 152 | 31 |
| Finasteride | Finasteride | 144 | 39 |
| Furosemide | Furosemide | 134 | 41 |
| Famotidine | Famotidine | 132 | 32 |
| Lorazepam | Lorazepam | 131 | 27 |
| Bupropion Xl | Bupropion Hcl | 124 | 33 |
| Atenolol | Atenolol | 110 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 28 |
| Allopurinol | Allopurinol | 98 | 27 |
| Glipizide | Glipizide | 98 | 21 |
| Prednisone | Prednisone | 94 | 73 |
| Ezetimibe | Ezetimibe | 89 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 24 |
| Spironolactone | Spironolactone | 86 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 12 |
| Ozempic | Semaglutide | 79 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 27 |
| Carvedilol | Carvedilol | 75 | 17 |
| Xarelto | Rivaroxaban | 75 | 17 |
| Azithromycin | Azithromycin | 73 | 52 |
| Amoxicillin | Amoxicillin | 72 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 69 | 12 |
| Potassium Chloride | Potassium Chloride | 69 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 16 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 16 |
| Jardiance | Empagliflozin | 62 | 16 |
| Mirtazapine | Mirtazapine | 62 | 11 |
| Metformin Hcl Er | Metformin Hcl | 61 | 21 |
| Pregabalin | Pregabalin | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Diazepam | Diazepam | 50 | 15 |
| Propranolol Hcl | Propranolol Hcl | 50 | 17 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 31 |
| Eliquis | Apixaban | 47 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Xifaxan | Rifaximin | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ramipril | Ramipril | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,857.90 · 119 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Auvelity, BEXSERO, BEYFORTUS, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, Heplisav-B, JARDIANCE, JOURNAVX, Kerendia, M-M-R II, MENQUADFI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, PENBRAYA, PREVNAR 20, Paragard T 380A, QULIPTA, REPATHA, REXULTI, ROTARIX, Rybelsus, SHINGRIX, SYNTHROID, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error